Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11600
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ebert, Lisa M | en |
dc.contributor.author | MacRaild, Sarah E | en |
dc.contributor.author | Zanker, Damien | en |
dc.contributor.author | Davis, Ian D | en |
dc.contributor.author | Cebon, Jonathan S | en |
dc.contributor.author | Chen, Weisan | en |
dc.date.accessioned | 2015-05-16T01:12:58Z | |
dc.date.available | 2015-05-16T01:12:58Z | |
dc.date.issued | 2012-10-26 | en |
dc.identifier.citation | PLoS One 2012; 7(10): e48424 | en |
dc.identifier.govdoc | 23110239 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11600 | en |
dc.description.abstract | Cancer vaccines are designed to expand tumor antigen-specific T cells with effector function. However, they may also inadvertently expand regulatory T cells (Treg), which could seriously hamper clinical efficacy. To address this possibility, we developed a novel assay to detect antigen-specific Treg based on down-regulation of surface CD3 following TCR engagement, and used this approach to screen for Treg specific to the NY-ESO-1 tumor antigen in melanoma patients treated with the NY-ESO-1/ISCOMATRIX™ cancer vaccine. All patients tested had Treg (CD25(bright) FoxP3(+) CD127(neg)) specific for at least one NY-ESO-1 epitope in the blood. Strikingly, comparison with pre-treatment samples revealed that many of these responses were induced or boosted by vaccination. The most frequently detected response was toward the HLA-DP4-restricted NY-ESO-1(157-170) epitope, which is also recognized by effector T cells. Notably, functional Treg specific for an HLA-DR-restricted epitope within the NY-ESO-1(115-132) peptide were also identified at high frequency in tumor tissue, suggesting that NY-ESO-1-specific Treg may suppress local anti-tumor immune responses. Together, our data provide compelling evidence for the ability of a cancer vaccine to expand tumor antigen-specific Treg in the setting of advanced cancer, a finding which should be given serious consideration in the design of future cancer vaccine clinical trials. | en |
dc.language.iso | en | en |
dc.subject.other | Cancer Vaccines.therapeutic use | en |
dc.subject.other | Cells, Cultured | en |
dc.subject.other | Epitopes.immunology | en |
dc.subject.other | Flow Cytometry | en |
dc.subject.other | Humans | en |
dc.subject.other | Leukocytes, Mononuclear.metabolism | en |
dc.subject.other | Melanoma.immunology.pathology.therapy | en |
dc.subject.other | T-Lymphocytes, Regulatory.immunology | en |
dc.title | A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | PLoS One | en |
dc.identifier.affiliation | Ludwig Institute for Cancer Research (Melbourne-Austin Branch), Melbourne, Australia | en |
dc.identifier.doi | 10.1371/journal.pone.0048424 | en |
dc.description.pages | e48424 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/23110239 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Cebon, Jonathan S | |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.